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Abstract
Background: In schizophrenia, sex specific dimorphisms related to age of onset, course of illness and response to
antipsychotic treatment may be mirrored by sex-related differences in the underlying molecular pathways.
Methodology/Principal Findings: Here, we have carried out multiplex immunoassay profiling of sera from 4 independent
cohorts of first episode antipsychotic naive schizophrenia patients (n = 133) and controls (n = 133) to identify such sex-
specific illness processes in the periphery. The concentrations of 16 molecules associated with hormonal, inflammation and
growth factor pathways showed significant sex differences in schizophrenia patients compared with controls. In female
patients, the inflammation-related analytes alpha-1-antitrypsin, B lymphocyte chemoattractant BLC and interleukin-15
showed negative associations with positive and negative syndrome scale (PANSS) scores. In male patients, the hormones
prolactin and testosterone were negatively associated with PANSS ratings. In addition, we investigated molecular changes
in a subset of 33 patients before and after 6 weeks of treatment with antipsychotics and found that treatment induced sex-
specific changes in the levels of testosterone, serum glutamic oxaloacetic transaminase, follicle stimulating hormone,
interleukin-13 and macrophage-derived chemokine. Finally, we evaluated overlapping and distinct biomarkers in the sex-
specific molecular signatures in schizophrenia, major depressive disorder and bipolar disorder.
Conclusions/Significance: We propose that future studies should investigate the common and sex-specific aetiologies of
schizophrenia, as the current findings suggest that different therapeutic strategies may be required for male and female
patients.
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Introduction
Schizophrenia is a severe psychiatric illness with a lifetime
risk between 0.5 and 1% [1]. Despite the similar prevalence in
males and females, sex differences have been established for
many characteristics of the disorder [2]. These include age of
onset (typically younger in males), and differential symptoms,
disease course and treatment response. Numerous studies have
explored structural and neurophysiological sex dimorphisms of
schizophrenia by looking at specific molecules in a targeted
manner [2]. In particular, sex hormones have been hypothesised
as playing a central role in the differences in schizophrenia
between male and female patients. Estrogen has been shown to
have a variety of structural, functional and molecular functions
leading to protective effects in female schizophrenia patients. In
line with this, psychosis has been associated with lower estrogen
phases [2] and add-on estradiol treatment has been reported to
be beneficial for symptom improvement [3]. Other studies have
tested the idea that testosterone may have deleterious effects on
brain function and the vulnerability threshold to schizophrenia,
although the results of these investigations are inconclusive. In a
study using animal models treated with dopamine agonists and
antagonists, researchers demonstrated that treatment with
estradiol, but not testosterone, led to normalisation of the
behavioural effects [4]. On the other hand, an inverse
correlation between testosterone levels and negative symptom
severity was reported for men, and adjunctive androgen
treatment in male schizophrenia patients resulted in significant
improvement in negative symptoms [5].
PLOS ONE | www.plosone.org 1 November 2013 | Volume 8 | Issue 11 | e78729
Due to these sex-related differences, the theory has emerged
that males and females with schizophrenia may be affected by
different subtypes of the disorder [6–8]. This categorization of
sex-specific schizophrenia subtypes has been performed at the
clinical and developmental levels but no studies to date have
attempted to characterise the underlying molecular pathways.
Here, we have carried out multiplexed immunoassay profiling
analyses in a multi-centre study, comprising 4 independent
cohorts of 133 antipsychotic naive, first episode schizophrenia
patients and 133 well-matched healthy control subjects. In
addition, we used 5 cohorts comprised of 196 treated major
depressive disorder (MDD) patients and 7 cohorts of 92 treated
bipolar disorder (BPD) patients with matched controls to assess
sex-specific molecular markers of these illnesses. The immuno-
assay panel consisted of assays for immune factors, hormones,
growth factors, transport molecules and enzymes. This platform
has been used previously to explore molecular changes in
cancer, autoimmune disorders and cardiovascular diseases, as
well as in neurological disorders and various psychiatric diseases
such as schizophrenia [9–13].
The main objective of the present study was to determine
whether sex-specific molecular patterns can be identified in serum
of schizophrenia patients and if any of these could be related to
measures of symptom severity on the Positive and Negative
Syndrome Scale (PANSS). It was also of interest to determine if
similar differences occurred in 33 patients who received 6 weeks of
antipsychotic treatment. Finally, we examined shared and distinct
sex-specific biomarkers for schizophrenia, MDD, and BPD for the
same set of analytes.
Methods
Clinical Samples
All patients were suffering from the first illness episode and
were antipsychotic naive at the time of sample collection.
Samples were collected following strict standard operating
procedures over a period of 3 years. Samples were collected
between 8 AM and 10 AM, with no systematic differences
between patients and controls. Ethics statement: the ethical
committees of the participating hospitals at the Universities of
Cologne, Muenster and Magdeburg each approved the proto-
cols of the study, informed written consent was given by all
participants and studies were conducted according to the
Declaration of Helsinki. In cases where the participants may
have had a compromised capacity or ability to give consent,
next of kin, carer takers or guardians consented on their behalf.
All diagnoses were carried out using the Diagnostic and
Statistical Manual (DSM)-IV and clinical tests performed by
psychiatrists under Good Clinical Practice-compliance to min-
imize variability. Symptom severity was assessed using the
Positive and Negative Syndrome Scale (PANSS) rating system.
Clinicians had access to all detailed clinical files including
medical histories by proxy and referral letters from the general
practitioners. Patients and controls with severe substance abuse
and other medical conditions such as type 2 diabetes mellitus,
hypertension, endocrine abnormalities, cardiovascular or auto-
immune diseases were not included in the study. In addition,
controls with a family history of mental illness were excluded
from the study. The demographic details are shown in Table 1.
Cohort 1 was from University of Cologne Department of
Psychiatry, Germany; Cohort 2 was from University of
Muenster, Germany; and Cohorts 3 and 4 were from University
of Magdeburg, Germany. Males and females were matched
separately between patients and controls in each cohort
according to age, body mass index (BMI), waist circumference,
and tobacco and cannabis consumption where this information
available. There were no significant differences in these
variables between patients and controls and all participants
were white European. The same procedures were followed for
sample collection from treated major depressive disorder (MDD)
and bipolar disorder (BPD) patients and matching controls. The
majority of MDD and BPD patients were not in their first
episode of illness, and BPD patient type and mood state were
heterogeneous. Demographic details can be found in Tables
S1 and S2 in the File S1 for MDD and BPD patients,
respectively.
To investigate effects of antipsychotic treatment on biomarker
candidates, 33 patients from cohort 3 were also assessed before
and after a 6-week inpatient treatment period (Table 2). Male
and female patients tested in this phase of the study showed no
significant differences in age, BMI, smoking, cannabis use, or
PANSS scores before treatment. Blood samples were collected
from all subjects by venous puncture into S-Monovette 7.5 mL
serum tubes (Sarstedt; Numbrecht, Germany). Serum was
prepared using standard protocols by leaving samples at room
temperature for 2 hours to allow blood coagulation, followed by
centrifugation at 4,0006g for 5 minutes to remove particulate
material. The resulting supernatants were stored at 280uC in
LoBind Eppendorf tubes (Hamburg, Germany) prior to analysis.
Multiplexed Immunoassays
The protocol for the study participants, collection and storage of
clinical samples, and test methods were carried out in compliance
with the Standards for Reporting of Diagnostic Accuracy initiative
[14]. The HumanMAPH multiplex immunoassay platform was
used to screen the serum concentrations of 190 total analytes
across all samples in the separate cohorts. The screening was
carried out in a Clinical Laboratory Improvement Amendments-
certified laboratory at Myriad-RBM (Austin, TX, USA) as
described previously [13]. Samples were randomized and blinded
to analysts using coded numbers until all biochemical assays were
completed. Assays were calibrated using standards, raw intensity
measurements converted to absolute protein concentrations by
comparison to the standards, and performance was verified using
quality control samples.
Statistical Analysis
The multiplex immunoassay data were pre-processed by
screening for those analytes which gave robust readings within
the limits of quantitation in more than 70% of samples. This
resulted in 92 proteins and 3 steroid hormones, which represented
inflammation, hormonal, growth factor, cardiovascular system and
metabolism-related pathways (Table S3 in the File S1). Shapiro-
Wilk analysis showed that the majority of the values were not
distributed normally. Therefore, values were loge-transformed to
approximate normality. Outlying values for each analyte were
excluded if a given concentration differed by more than 3 standard
deviations from the mean after loge-transformation. For the
different analyses described in the present study, this resulted in
the removal of an average of approximately 0.7% of the values per
analyte.
The data for the combined cohorts were used first to identify
analytes which were present at significantly different levels in
schizophrenia compared to control subjects using cohort, age, and
sex as additional covariates in a linear model. Next, we calculated
sex-diagnosis interactions for each analyte using the same
additional covariates. In order to examine the robustness of our
findings against deviations from method assumptions and effects of
Sex-Related Biomarker Profiles in Schizophrenia
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covariate adjustment, we also performed interaction tests using the
non-parametric aligned rank transform method without using
additional covariates [15,16]. Analytes found to have significant
sex-diagnosis interactions (P,0.05 and Q,0.30) were stratified by
sex and re-analysed. This was repeated within each cohort to
investigate the consistency of sex-specific patterns. The same
procedure was used across all schizophrenia cohorts to identify
potential molecular interactions between sex and positive,
negative, and total PANSS scores in schizophrenia patients.
Average correlation coefficients between analyte levels and scores
across cohorts were found using Fisher’s z transformation [17].
The effect of treatment with antipsychotics on serum analyte levels
for 33 patients was evaluated using repeated measures analysis of
variance (ANOVA), with sex as a between subjects variable and
adjustment for analyte values at baseline. P-values were adjusted
for the false discovery rate to account for multiple comparisons
and control chance findings (FDR; given as Q values) according to
the method of Benjamini and Hochberg [18]. Analysis of MDD
and BPD cohorts followed the same procedure.
Raw data is stored in our database and can be made available
upon request.
Table 1. Schizophrenia patient demographics.
Cohort 1 Cohort 2 Cohort 3 Cohort 4 P-values
M F M F M F M F M F
Patients N 23 25 34 11 14 10 8 8 – –
Controls N 23 25 34 11 14 10 8 8 – –
Patients age 26.466 30.469 27.669 23.567 28.569 36.2614 33.3611 37.0612 0.81 0.75
Controls age 27.166 30.267 27.668 23.667 29.669 35.6614 32.069 34.3610
Patients BMI 22.862 23.165 22.762 20.962 23.764 25.365 22.262 21.263 0.55 0.67
Controls BMI 22.762 22.364 24.565 24.964 23.261 22.064
Patients tobacco 13/7/3 8/8/9 15/15/4 1/10/0 9/5/0 7/3/0 4/4/0 2/5/1 0.13 0.17
Controls tobacco 11/12/0 11/14/0 6/8/0 2/8/0 3/5/0 2/6/0
Patients cannabis 12/9/2 13/6/6 14/16/4 1/10/0 0/14/0 0/10/0 0/7/1 0/8/0 1.0 0.63
Controls cannabis 13/8/2 12/12/1 0/14/0 0/10/0 0/8/0 0/8/0
PANSS P1-P7 23.465 23.366 17.266 18.0610 22.467 18.866 14.465 23.969 – –
PANSS N1-N7 24.569 22.767 17.767 17.469 20.1610 18.369 14.962 16.465 – –
PANSS G1-G16 49.069 50.0610 37.6610 36.6613 44.3614 40.169 33.466 40.8615
Total PANSS 96.9619 96.0619 72.5620 72.0630 86.9627 77.2615 62.6611 81.0625 – –
Values are shown as mean6 sd. Tobacco and cannabis use is displayed as (yes/no/NA) and age is in years. M = male. F = female. N = number. BMI = body mass index (kg/
m2). PANSS = Positive and Negative Syndrome Scale. The final two columns show that there are no significant differences in age, BMI, smoking, or cannabis use between
schizophrenia patients and controls in the final combined cohort.
doi:10.1371/journal.pone.0078729.t001
Table 2. Demographics for treated schizophrenia cohort.
Antipsychotic follow-up
M F
Patients N 22 11
Patients age 29.268 34.6614
Patients BMI 23.564 25.065
Patients tobacco 16/22/0 8/3/0
Patients cannabis 8/14/0 1/10/0
T0 T6 T0 T6
PANSS P1–P7 22.367 12.064 19.466 10.964
PANSS N1–N7 1869 1567 20.2610 12.866
PANSS G1–G16 42.7612 28.569 42.3611 27.469
Total PANSS 83.1623 55.5618 81.8621 51.1615
Antipsychotic type (olanzapine/quetiapine/risperidone/other) 0 5/3/6/8 0 3/4/3/1
Cumulative chlorpromazine units (mg) 0 17 347614 928 0 15 254610 657
Patients were from cohort 3 and were initially antipsychotic naı¨ve. Values are shown as mean 6 sd. Tobacco and cannabis use is displayed as (yes/no/NA) and age is in
years. M = male. F = female. N = number. BMI = body mass index (kg/m2). PANSS = Positive and Negative Syndrome Scale. T0 = initial time point. T6 = after 6 weeks of
antipsychotic treatment.
doi:10.1371/journal.pone.0078729.t002
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Results
Identification of Analytes Altered in Schizophrenia
Patients Compared to Control Subjects
Multiplex immunoassay profiling of serum samples resulted in
identification of 65 analytes which were present at significantly
different levels between schizophrenia patients and controls after
adjustment for cohort, age, and sex (Table 3). Forty-one analytes
are shown with Q,0.10. The analytes showing the largest
ratiometric differences included ferritin, macrophage migration
inhibitory factor, carcinoembryonic antigen and haptoglobin,
which were all more than 1.5-fold higher in schizophrenia patients
compared to controls. Epidermal growth factor was decreased by
more than 1.5 fold. Seven of these 41 analytes showed significant
interactions of diagnosis with sex. These were ferritin, testosterone
(total and free), alpha-1-antitrypsin, thyroxine binding globulin,
interleukin (IL)-15, macrophage-derived chemokine (MDC) and
angiotensin-converting enzyme.
Sex Specificity of Schizophrenia Biomarkers
The second part of this study was targeted at the identification
of analytes with significantly different concentrations between
males and females in schizophrenia (P,0.05 and Q,0.30). This
resulted in identification of 16 molecules with significant diagnosis-
sex interactions across the 4 cohorts. We also approximated free
testosterone levels using the ratio of total testosterone to sex
hormone binding globulin (SHBG) and found a significant
diagnosis-sex interaction (P,0.001). We obtained qualitatively
similar results using a non-parametric interaction test without
covariate adjustment. For ease of interpretation, all analytes with
significant interactions were categorized as ‘‘male-specific’’,
‘‘female-specific’’ or ‘‘qualitative interaction’’, depending on
whether the respective abnormalities occurred only in males, only
in females or in both sexes but with opposite directional changes
(Table 4). This analysis showed that serum from male schizo-
phrenia patients contained higher levels of ferritin, alpha-1-
antitrypsin, MDC, thyroxine binding globulin, IL-15, macrophage
inflammatory protein-1 alpha (MIP-1 alpha), intracellular adhe-
sion molecule (ICAM)-1 and epithelial-derived neutrophil-activat-
ing protein (ENA)-78. Female sera contained higher levels of total
and free testosterone, and lower levels of angiotensin-converting
enzyme (ACE) and vascular endothelial growth factor (VEGF). We
also measured the prolactin/growth hormone and insulin/growth
hormone ratios as these are known to be affected in insulin
resistant states, which can occur in some schizophrenia patients
[19–21]. We found higher ratios for both of these in sera from
female patients. The levels of B lymphocyte chemoattractant
(BLC), prolactin, SHBG, stem cell factor (SCF) and growth
hormone showed qualitative interactions with changes seen in
opposite directions between male and female patients. The
majority of analytes with significant overall sex-diagnosis interac-
tions also showed similar sex-specific trends within individual
cohorts (Table S4 in the File S1), although there was substantial
variation in patterns for levels of prolactin and growth hormone.
Sex Specificity of Major Depressive Disorder and Bipolar
Disorder Markers
In order to examine molecular sex differences in other
psychiatric diseases, we calculated sex-diagnosis interactions for
the same set of analytes in groups of treated MDD and BPD
patients and matched controls. We found 3 molecules with
significant sex-diagnosis interactions in MDD that included higher
levels of ferritin and lower levels of immunoglobulin A (IgA) in
male MDD patients, along with lower growth hormone concen-
trations in females (Table S5 in the File S1). In BPD, 7
molecules were found with sex-specific signatures, with lower male
analyte levels of insulin-like growth factor binding protein 2
(IGFBP2) and myoglobin, and higher granulocyte-colony stimu-
lating factor (GCSF) and haptoglobin levels (Table S6 in the
File S1). As in MDD, female BPD patients had lower serum levels
of growth hormone. Chromogranin A and AXL receptor tyrosine
kinase concentrations showed qualitative interactions in BPD.
Sex Specific Associations between Analytes and PANSS
Ratings
In the next part of the study, we investigated the relationship of
positive, negative, and total PANSS ratings in schizophrenia
patients using the panel of sex-specific biomarkers. We found that
5 molecules showed sex differences in their associations with
symptom severity (Table 5). In female patients, the inflammation-
related analytes alpha-1-antitrypsin, BLC and IL-15 showed
negative associations with positive and total PANSS, positive
PANSS, and negative and total PANSS, respectively. In male
patients, the hormones prolactin and testosterone were negatively
associated with positive PANSS ratings.
Sex Specific Effects on Analytes Following Schizophrenia
Treatment
To test for sex specific effects of antipsychotic treatment, serum
was analyzed from 33 antipsychotic naive schizophrenia patients
before and after 6 weeks of inpatient treatment (Table 2). Of the
analytes with significant diagnosis-sex interactions described
above, antipsychotic treatment induced significant changes in
the levels of 4 molecules (ICAM-1, ACE, prolactin and SHBG)
and sex-specific changes were found for two analytes (testosterone
and MDC). The largest change was observed for prolactin, which
was increased 2.54-fold following treatment.
We tested the same serum samples for effects of treatment on all
95 analytes measured using the multiplex immunoassay platform.
This resulted in identification of 5 analytes [testosterone, serum
glutamic oxaloacetic transaminase (SGOT), follicle stimulating
hormone (FSH), IL-13, and MDC] which showed differential
changes, dependent on sex (Table 6). Levels of SGOT were
increased and IL-13 was decreased specifically in females while
free testosterone was increased in males. MDC levels were
significantly elevated in both sexes, but greater changes were seen
in females.
Discussion
This is the first multiplexed immunoassay study to address the
question of whether sex-specific molecular differences can be
identified in the circulation of schizophrenia patients. The first
phase of the study was aimed at detection of serum analytes which
were present at significantly different levels in schizophrenia
patients compared to controls. This resulted in identification of 41
analytes, 33 of which have identified in previous multiplex
immunoassay profiling studies of schizophrenia and control
subjects [12,13,22,23]. As described previously, these analytes
represented hormonal (cortisol, luteinizing hormone, follicle-
stimulating hormone, pancreatic polypeptide, progesterone, re-
sistin, chromogranin A and leptin); growth factor (sortilin,
epidermal growth factor, insulin-like growth factor binding protein
2, hepatocyte growth factor); inflammation (macrophage migra-
tion inhibitory factor, alpha-2-macroglobulin, haptoglobin, carci-
noembryonic antigen, interleukin-8, interleukin-10, complement
C3, CD40 ligand, tissue inhibitor of metalloproteinases 1, alpha-1-
antitrypsin, RANTES, tumour necrosis factor receptor 2, serum
Sex-Related Biomarker Profiles in Schizophrenia
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amyloid P and eotaxin); and other (apolipoprotein CIII, apolipo-
protein A1, prostatic acid phophatase) pathways. Combining
multiple cohorts, increasing power and reliability of findings,
resulted in the identification of 7 novel molecules associated with
schizophrenia in this study. Three of these molecules showed sex-
specific changes in schizophrenia.
The most novel outcome of the current study was the finding
that 16 molecules showed significant sex-diagnosis interactions.
Most of these molecules have been associated previously with
schizophrenia, albeit not in a manner stratified by sex. In a
previous study, we identified reproducible changes in alpha-1-
antitrypsin, ferritin, intracellular adhesion molecule (ICAM)-1,
Table 3. Multiplex immunoassay profiling analysis of schizophrenia and control samples across the combined cohorts.
P Q R
Ferritin* ,0.001 ,0.001 2.23
Macrophage migration inhibitory factor (MIF) ,0.001 ,0.001 1.88
Cortisol ,0.001 ,0.001 1.42
Alpha-2-macroglobulin ,0.001 ,0.001 1.16
Haptoglobin ,0.001 ,0.001 1.57
Carcinoembryonic antigen ,0.001 ,0.001 1.59
Testosterone* ,0.001 ,0.001 1.23
Sortilin ,0.001 ,0.001 0.85
Interleukin-8 ,0.001 ,0.001 1.34
Interleukin-10 ,0.001 0.001 1.11
Epidermal growth factor ,0.001 0.002 0.62
Complement C3 0.002 0.013 1.07
Apolipoprotein C-III 0.002 0.018 0.88
CD40 ligand 0.003 0.018 0.72
Tissue inhibitor of metalloproteinases 1 0.004 0.026 1.06
Free testosterone* 0.005 0.028 1.26
Alpha-1-antitrypsin* 0.005 0.028 1.07
Luteinizing hormone 0.005 0.028 1.29
Pancreatic polypeptide 0.006 0.028 1.42
Apolipoprotein A-1 0.006 0.028 0.89
Follicle stimulating hormone 0.007 0.035 1.27
T cell specific protein RANTES (RANTES) 0.008 0.036 1.17
Prostatic acid phosphatase 0.008 0.036 0.89
Thyroxine binding globulin* 0.010 0.040 1.08
Progesterone 0.010 0.041 1.18
Resistin 0.012 0.045 0.88
Tumor necrosis factor receptor-like 2 (TNFR2) 0.014 0.045 1.08
Insulin-like growth factor-binding protein 2 (IGFBP-2) 0.014 0.045 1.15
Interleukin-15* 0.015 0.045 1.17
Hepatocyte growth factor 0.015 0.045 1.17
Chromogranin A 0.015 0.045 1.34
Serum amyloid P 0.015 0.045 1.09
Receptor for advanced glycosylation end products (RAGE) 0.016 0.045 0.87
Macrophage-derived chemokine (MDC)* 0.016 0.045 1.09
EN-RAGE 0.017 0.048 1.26
Creatine kinase-MB 0.018 0.048 0.82
Tenascin-C 0.024 0.064 1.12
Eotaxin 0.025 0.065 1.15
Angiotensin converting enzyme (ACE)* 0.029 0.073 0.88
Factor VII 0.034 0.082 0.92
Leptin 0.035 0.084 0.78
P = p-value. Q = p-value adjusted for the false discovery rate. R = ratio (schizophrenia/control) using geometric means. Analytes with an asterisk showed a significant
diagnosis gender interaction. Analytes in bold font have been identified in previous multiplex immunoassay profiling analyses of schizophrenia and control patients.
doi:10.1371/journal.pone.0078729.t003
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MDC, prolactin, testosterone and VEGF [12]. The current results
suggest that at least some of these differences could have been
driven by specific molecular abnormalities in either male or female
schizophrenia patients. In line with the numerous sex differences
reported in schizophrenia, our findings included alterations in the
levels of several hormones. Higher levels of free and total
testosterone in female patients and concomitant sex differences
in SHBG concentrations were among the most statistically
significant findings. Disparity in the levels of testosterone have
been associated with normal sex differences of cerebral activation
during mental rotation and these patterns have been shown to be
reversed in schizophrenia [24]. Mendrek et al. have hypothesized
Table 4. Summary of significant diagnosis-sex interactions in schizophrenia and treatment effects on the levels of analytes.
Interaction Males Females Treatment Main Effect
P Q R P R P R P
Male specific
Ferritin 0.002 0.04 2.89 ,0.001 1.51 0.027 0.86 0.082
Alpha-1-antitrypsin 0.043 0.26 1.11 ,0.001 1.01 0.81 0.97 0.26
MDC 0.006 0.09 1.19 ,0.001 0.97 0.60
Thyroxine binding globulin 0.039 0.25 1.13 ,0.001 1.00 0.92 1.04 0.23
Interleukin-15 0.017 0.16 1.33 ,0.001 0.96 0.77 0.85 0.30
MIP-1 alpha 0.016 0.16 1.13 0.003 0.99 0.54 0.97 0.28
ICAM-1 0.019 0.16 1.11 0.008 0.97 0.45 1.14 0.006
ENA-78 0.048 0.27 1.18 0.027 0.93 0.45 1.05 0.16
Female specific
Testosterone ,0.001 0.03 1.10 0.062 1.51 ,0.001
Free testosterone ,0.001 0.002 0.94 0.42 2.01 ,0.001
ACE 0.015 0.16 0.99 0.87 0.74 0.002 1.21 ,0.001
VEGF 0.034 0.25 1.03 0.65 0.86 0.011 1.00 0.93
Prolactin/growth hormone 0.007 0.10 0.66 0.17 2.36 0.008 3.94 0.015
Insulin/growth hormone 0.038 0.25 0.72 0.42 2.54 0.015 1.44 0.47
Qualitative interaction
BLC ,0.001 0.03 1.73 0.009 0.59 0.035 1.45 0.17
Prolactin 0.038 0.25 0.90 0.32 1.33 0.062 2.54 ,0.001
SHBG 0.001 0.04 1.15 0.030 0.74 0.023 0.81 0.008
Stem cell factor 0.012 0.16 1.06 0.17 0.88 0.035 1.06 0.10
Growth hormone 0.040 0.25 1.41 0.21 0.58 0.079 0.64 0.35
Analytes were grouped into male or female specific sets accordingly. P = p-value. Q = p-value adjusted for the false discovery rate. R = ratio (schizophrenia/control;
follow-up/baseline) using geometric means. Significant treatment effects are shown in bold. MDC = macrophage-derived chemokine. MIP-1 alpha = macrophage
inflammatory protein-1 alpha. ICAM-1 = intracellular adhesion molecule-1. ENA-78 = epithelial-derived neutrophil-activating protein-78. ACE = angiotensin-converting
enzyme. VEGF = vascular endothelial growth factor. BLC = B lymphocyte chemoattractant. SHBG = sex hormone binding globulin.
doi:10.1371/journal.pone.0078729.t004
Table 5. Summary of sex-specific associations with positive, negative, and total PANSS score ratings.
A1AT IL-15 BLC PRL TT
Interaction Positive PANSS 0.012 0.039 0.032 0.037 0.018
Male 20.39 (0.017) 20.37 (0.010)
Female 20.35 (0.028) 20.47 (0.010) 20.23 (0.128)
Interaction Negative PANSS 0.004
Male
Female 20.47 (0.001)
Interaction Total PANSS 0.018 0.003
Male
Female 20.28 (0.047) 20.32 (0.004)
Only molecules with significant diagnosis-sex interactions were investigated. A1AT = alpha-1-antitrypsin. BLC = B lymphocyte chemoattractant. PRL = prolactin. TT = total
testosterone. The tabulated values are the average correlation coefficient from Fisher’s z transformation from linear model and (P-values).
doi:10.1371/journal.pone.0078729.t005
Sex-Related Biomarker Profiles in Schizophrenia
PLOS ONE | www.plosone.org 6 November 2013 | Volume 8 | Issue 11 | e78729
that this reversal of sex dimorphism is due to alterations in sex
hormone levels in both males and females during neurodevelop-
ment at the organization and activation stages, consistent with the
timing of onset in schizophrenia in adolescence or early adulthood
[25]. The current study puts this finding in the context of co-
occurring sexually dimorphic molecular changes. SHBG binds to
sex hormones like testosterone, affecting their bioavailability to
target cells. This protein was decreased in female schizophrenia
patients in parallel with increased free and total testosterone and
differences in prolactin and growth hormone levels. Decreased
SHBG has been reported in female schizophrenia patients after
treatment with atypical antipsychotics, in association with
increased prolactin levels [26,27].
Though insulin resistance was not directly measured in this
study, we determined the balance between insulin, growth
hormone, and prolactin as an indirect indication of this
phenomenon. Previous studies have suggested that 30–50% of
first onset schizophrenia patients show signs of impaired insulin
signalling [28]. Our finding of higher prolactin/growth hormone
and insulin/growth hormone ratios in female first onset schizo-
phrenia patients suggests that this effect could also be sex-specific.
Circulating prolactin improves glucose homeostasis by increasing
insulin action and secretion [19]. Conversely, high levels of growth
hormone can result in insulin antagonistic effects including insulin
resistance, stimulation of lipolysis, and inhibition of glucose
transport [20]. Studies using growth hormone and growth
hormone receptor knockout mice found increased insulin sensi-
tivity and higher prolactin levels, as well as increased life
expectancy compared to wild type mice [21]. Taken together,
these findings suggest that female schizophrenia patients may show
signs of better insulin signalling, which may afford some protection
against development of more severe psychiatric symptoms and
disease associated deficits.
Finally, molecular differences were also found specifically in
male patients and these were mainly related to pathways involved
in the inflammatory response. We found higher levels of ferritin in
males with schizophrenia, an acute phase reactant protein elevated
in the course of many diseases. Higher levels of this transport
protein have also been associated with a younger age of onset in
Alzheimer’s and Parkinson’s disease [29]. We found several
additional analytes related to acute phase and the inflammatory
response present at higher levels only in male patients. This raises
the possibility that some aspects of the widely-reported immuno-
logical abnormalities in schizophrenia may be specific for males.
However, other inflammation-related molecules including alpha-
1-antitrypsin, IL-15 and BLC were related to positive, negative,
and total symptom severity in females. Taken together, these
findings suggest that different components of the inflammatory
and immune responses may behave differently in male and female
patients with schizophrenia.
We were unable to evaluate precisely the specificity of these
results to schizophrenia by comparison with other psychiatric
illnesses due to the rarity of first onset, drug naive patients.
However, we examined sex-diagnosis interactions for the same
analytes in a combination of treated, drug free, and drug naive
MDD and treated BPD patients. We found an overlap in the sex-
specific signature for growth hormone in both illnesses and also for
ferritin in MDD. A study of sex-specific serum biomarkers using
the same analytes in adults with Asperger syndrome (AS; AS= 45,
control = 50) revealed elevated levels of free testosterone specifi-
cally in females and similar patterns of sex differences in growth
hormone and SHBG concentrations compared to the current
study of schizophrenia patients and controls [30]. These findings
reveal similar and distinct sex-specific molecular patterns in
psychiatric disease. Larger and better characterized cohorts of first
onset, drug naive major depression, bipolar disorder, and other
psychiatric disorder patients would be required to adequately
evaluate the specificity of the sex-specific molecular phenotype of
schizophrenia.
The present findings suggest that sex-specific differences occur
in the response and role of hormones, growth factors, cardiovas-
cular and inflammation pathways in schizophrenia. However,
there are several limitations which will require further work. For
example, larger cohorts for replication and better characterized
samples will be needed. Fewer female patient samples were
available, reducing the power to detect molecular differences in
this group. Larger cohort sizes and more female patient samples
would facilitate studies of the effects of age on sex-specific
molecular signatures of schizophrenia as levels of estrogen in
females decline. In addition, we cannot account for unrecorded
potential confounding factors such as BMI, tobacco, and cannabis
consumption in some cohorts. Information on other prescription
drug use including contraceptive medication and other variables
like socioeconomic status, fasting status, blood pressure, meno-
pausal status, and phase of menstrual cycle were also unavailable
for all cohorts. However, the size and number of cohorts in this
study are likely to compensate for potential confounders and
provides a naturalistic clinical scenario. Finally, stricter signifi-
cance cut-offs using adjusted p-values would have lead to different
results and interpretation of this study, though internal replication
between cohorts showed consistent patterns for most analytes.
A small scale longitudinal study showed that antipsychotic
treatment led to significant sex-specific changes in testosterone and
MDC, providing further evidence of the potential effect of sex on
the role of these molecules in schizophrenia. We also found SGOT
increased specifically in females using antipsychotics, which may
be related to weight gain [31]. In addition to the metabolic side
effects of antipsychotics, cardiovascular mortality and hyperten-
sion are more prevalent in patients with psychotic illness [32].
These are potentially associated with the elevation in concentra-
tions of ACE and ICAM-1 we found in patients over the course of
antipsychotic treatment. Previous investigations have also reported
increased prolactin and decreased SHBG levels following atypical
antipsychotic administration and these findings are replicated here
[26,27,33,34]. Larger follow-up studies will be necessary to
investigate the sex-specific modulation of schizophrenia biomarker
candidates. Further exploration is also warranted into the
mechanisms by which these sexually distinct molecular phenotypes
in schizophrenia arise. This may lead to deeper insights into the
Table 6. Summary of analytes with sex-specific treatment
effects.
Interaction Males Female
P R P R P
Testosterone 0.003 1.12 0.11 0.84 0.36
Serum glutamic oxaloacetic
transaminase
0.006 0.93 0.27 1.34 0.032
Free testosterone 0.009 1.37 0.004 1.07 0.80
Follicle stimulating hormone 0.021 1.01 0.84 0.62 0.10
Interleukin-13 0.026 1.01 0.79 0.87 0.012
Macrophage-derived chemokine 0.039 1.14 0.003 1.27 ,0.001
P = p-value. R = ratio (follow-up/baseline) using geometric means.
doi:10.1371/journal.pone.0078729.t006
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well established sex differences in the clinical manifestation and
course of schizophrenia which, in turn, could lead to the
development of novel treatment approaches for improved patient
outcomes.
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